BHVN Stock Forecast: Biohaven Ltd. Price Predictions for 2026-2027
The 17 Wall Street analysts covering Biohaven Ltd. hold a median 12-month price target of $26 — +110.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Biohaven Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (79): Sales and profits are climbing, and climbing faster than before.
Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BHVN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BHVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +110.1% from it.
Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | Morgan Stanley | Maintains | Overweight | $19 → $21 |
| 31 Oct 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 Oct 2026 | Canaccord Genuity | Maintains | Buy | $21 → $32 |
| 23 Oct 2026 | RBC Capital | Maintains | Sector Perform | $19 → $22 |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | $10 |
| 8 Sept 2026 | RBC Capital | Downgrade | Sector Perform | $23 → $19 |
| 12 Aug 2026 | Morgan Stanley | Maintains | Overweight | $18 → $19 |
| 11 Aug 2026 | RBC Capital | Maintains | Outperform | $22 → $23 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | $12 → $11 |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 13 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 5 May 2026 | RBC Capital | Maintains | Outperform | — |
| 2 Apr 2026 | Citigroup | Maintains | Buy | — |
| 11 Mar 2026 | TD Cowen | Maintains | Buy | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 3 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 21 Jan 2026 | RBC Capital | Upgrade | Outperform | — |
| 6 Jan 2026 | Morgan Stanley | Maintains | Overweight | — |
| 26 Dec 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 3 Dec 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BHVN.
This page is one stock. Monday covers all of them.
BHVN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BHVN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Biohaven Ltd. returned +28.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BHVN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 172.4×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −1418.8%
- Return on assets
- −90.6%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biohaven Ltd. has a market value of $2.1B and an enterprise value of $2.2B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$586.8M.
Diluted earnings per share, trailing twelve months: −$4.64.
Free cash flow in the twelve months to 30 June 2026: −$511.9M.
Biohaven Ltd. employs 274 people.
Data provided by Twelve Data
BHVN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BHVN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Biohaven Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BHVN
What is the BHVN stock price forecast for 2026-2027?
The 17 Wall Street analysts covering Biohaven Ltd. have a median 12-month price target of $26, with estimates ranging from $9 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BHVN stock a buy right now?
Of the 17 analysts covering Biohaven Ltd., 12 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biohaven Ltd. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BHVN?
As at 21 Nov 2026, Biohaven Ltd. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).
Will BHVN stock go up?
No one can know that. What the data says: the median 12-month target from 17 analysts implies +110.1% from the last close, and Ticker Nerd's factor model ranks Biohaven Ltd. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BHVN stock forecast for 2030?
No analyst covering Biohaven Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $48 over the next 12 months.
How has BHVN stock performed over the past year?
Biohaven Ltd. returned +28.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Biohaven Ltd. do?
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology. The company’s current portfolio includes drug candidates for neurological and neuropsychiatric disorders, epilepsy, pain, neuroinflammatory conditions, and rare diseases, alongside programs aimed at immune-mediated and cancer-related indications.
About Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology. The company’s current portfolio includes drug candidates for neurological and neuropsychiatric disorders, epilepsy, pain, neuroinflammatory conditions, and rare diseases, alongside programs aimed at immune-mediated and cancer-related indications. Biohaven uses multiple proprietary development platforms, including approaches such as ion channel modulation, extracellular protein degradation, and antibody-drug conjugates, to build a diversified pipeline of investigational medicines. Headquartered in New Haven, Connecticut, Biohaven serves as a research-driven biopharmaceutical platform centered on advancing novel treatments across both common and underserved disease areas.
CEO Dr. Vladimir Coric M.D. · 274 employees · United States · https://www.biohaven.com